High-density lipoproteins as therapeutic targets
Authors:
- Stephen J NichollsSNStephen J Nicholls
- Kerry-Anne RyeKRKerry-Anne Rye
- Philip J BarterPBPhilip J Barter
- 1 June 2005
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Lipidology
- Vol. 16 (3) , 345-349
Abstract
The concentration of cholesterol in HDL is an inverse predictor of future cardiovascular disease, with evidence mounting that therapies that increase HDL concentration are antiatherogenic. The best known antiatherogenic function of HDL particles relates to their ability to promote the efflux of cholesterol from cells. However, they also have antioxidant, antiinflammatory and antithrombotic properties. The past year has seen the publication of several papers that highlight a potential major protective role of HDL in states of acute inflammation. Papers showing extremely promising results using novel inhibitors of cholesteryl ester transfer protein as HDL-raising agents have also appeared. Finally, the discovery that ATP-binding cassette transporter G1 (ABCG1) transports cell cholesterol to large HDL particles in the extracellular space has largely reconciled apparent inconsistencies between basic research indicating that small, pre-β-migrating HDL particles are the antiatherogenic components of HDL and epidemiological research that implicates larger HDL particles as the protective fraction. The finding that ABCG1 promotes the efflux of cholesterol from cells to large HDL particles also provides powerful circumstantial evidence that cholesteryl ester transfer protein inhibition (which increases HDL size) may enhance, rather than reduce, cholesterol efflux, and thus inhibit the development of atherosclerosis.Keywords
This publication has 29 references indexed in Scilit:
- High-Density Lipoprotein Stimulates Myocardial Perfusion In VivoCirculation, 2004
- High-Density Lipoproteins Neutralize C-Reactive Protein Proinflammatory ActivityCirculation, 2004
- HIGH-DENSITY LIPOPROTEINS REDUCE THE INTESTINAL DAMAGE ASSOCIATED WITH ISCHEMIA/REPERFUSION AND COLITISShock, 2004
- High-Density Lipoproteins in Sepsis and Septic Shock: Metabolism, Actions, and Therapeutic ApplicationsShock, 2004
- Reconstituted High-Density Lipoprotein Attenuates Organ Injury and Adhesion Molecule Expression in a Rodent Model of Endotoxic ShockShock, 2003
- Effect of Recombinant ApoA-I Milano on Coronary Atherosclerosis in Patients With Acute Coronary SyndromesJAMA, 2003
- Inhibition of Atherosclerosis Development in Cholesterol-Fed Human Apolipoprotein A-I–Transgenic RabbitsCirculation, 1996
- Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse.Proceedings of the National Academy of Sciences of the United States of America, 1994
- Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit.Journal of Clinical Investigation, 1990
- High density lipoprotein as a protective factor against coronary heart diseaseThe American Journal of Medicine, 1977